Amgen profit ex-items tops Wall Street view; rebounds after 1st qtr
July 30 (Reuters) - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.
Most of Amgen's higher profile products had sales that exceeded Wall Street estimates, and the world's largest biotechnology company raised its full-year earnings forecast.
Amgen posted a net profit of $1.26 billion, or $1.65 per share, compared with a profit of $1.26 billion, $1.61 per share, a year ago
Excluding special items, Amgen earned $1.89 per share. Analysts on average expected $1.74, according to Thomson Reuters I/B/E/S.
- Ford leans on global Mustang to burnish overseas image
- Gunmen kill U.S. teacher in Libya's Benghazi
- Obama says he's not allowed iPhone for 'security reasons'
- Special Report: Thailand secretly supplies Myanmar refugees to trafficking rings |
- U.S. fast-food workers walk off job, rally for higher minimum wage